TP53 and cancer: Among the patients with LFS who developed cancer (n = 63), the wildtype TP53 patients (n = 14) had a greater burden of P/LP variants in CPG (class 1–2; Wilcoxon rank-sum test, P = 3.9 × 10−4; Supplementary Fig. S4) and cancer genes (class 1–3; Wilcoxon rank-sum test, P = 2.9 × 10−3) compared with the variant TP53 cohort (n = 49; Fig. 2G).